Liberum Capital Reaffirms a “Hold” Rating on UDG Healthcare PLC (LON:UDG) and GBX 884.00 Target; CES Energy Solutions Corp. (TSE:CEU) Covered By 5 Bulls

London: In a report shared with investors on 30 January, Liberum Capital maintained their “Hold” rating on shares of UDG Healthcare PLC (LON:UDG). They currently have a GBX 884.00 PT on the company. Liberum Capital’s target suggests a potential upside of 8.13% from the company’s close price.

Among 6 analysts covering Canadian Energy Services & Technology Corp. (TSE:CEU), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Canadian Energy Services & Technology Corp. has $87 highest and $2 lowest target. $18.39’s average target is 192.37% above currents $6.29 stock price. Canadian Energy Services & Technology Corp. had 25 analyst reports since August 13, 2015 according to SRatingsIntel. Scotia Capital maintained the stock with “Outperform” rating in Thursday, June 9 report. The rating was maintained by National Bank Canada with “Outperform” on Tuesday, December 15. The company was maintained on Tuesday, January 10 by Canaccord Genuity. The stock of CES Energy Solutions Corp. (TSE:CEU) earned “Market Perform” rating by Raymond James on Friday, October 7. Scotia Capital maintained the stock with “Focus Stock” rating in Thursday, August 13 report. BMO Capital Markets maintained CES Energy Solutions Corp. (TSE:CEU) on Monday, May 15 with “Outperform” rating. See CES Energy Solutions Corp. (TSE:CEU) latest ratings:

The stock decreased 3.68% or $0.24 during the last trading session, reaching $6.29. About 969,358 shares traded or 50.27% up from the average. CES Energy Solutions Corp. (TSE:CEU) has 0.00% since January 30, 2017 and is . It has underperformed by 16.70% the S&P500.

CES Energy Solutions Corp., together with its subsidiaries, provides consumable chemical solutions throughout the life-cycle of the oilfield. The company has market cap of $1.68 billion. The firm provides solutions at the drill-bit, at the point of completion and stimulation, at the wellhead and pump-jack, and through to the pipeline and midstream market. It has a 59.34 P/E ratio. The Company’s solutions include corrosion inhibitors, demulsifiers, H2S scavengers, paraffin control products, surfactants, scale inhibitors, biocides, and other specialty products.

The stock decreased 0.55% or GBX 4.5 during the last trading session, reaching GBX 807.5. About 281,327 shares traded. UDG Healthcare plc (LON:UDG) has 0.00% since January 30, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 10 analysts covering UDG Healthcare PLC (LON:UDG), 4 have Buy rating, 1 Sell and 5 Hold. Therefore 40% are positive. UDG Healthcare PLC has GBX 940 highest and GBX 5.15 lowest target. GBX 843.13’s average target is 4.41% above currents GBX 807.5 stock price. UDG Healthcare PLC had 99 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, February 7 by Cantor Fitzgerald. The rating was maintained by Berenberg with “Hold” on Wednesday, November 18. Jefferies maintained the shares of UDG in report on Friday, September 30 with “Buy” rating. The stock of UDG Healthcare plc (LON:UDG) has “Hold” rating given on Wednesday, September 28 by Stifel Nicolaus. On Thursday, November 24 the stock rating was maintained by Goodbody with “Buy”. The rating was maintained by Liberum Capital with “Hold” on Tuesday, January 30. The firm has “Outperform” rating by Davy Research given on Monday, October 24. The company was maintained on Thursday, November 24 by Numis Securities. Berenberg maintained the shares of UDG in report on Friday, November 18 with “Buy” rating. The stock of UDG Healthcare plc (LON:UDG) has “Hold” rating given on Monday, May 8 by Berenberg.

UDG Healthcare plc, together with its subsidiaries, provides clinical, commercial, communication, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and continental Europe. The company has market cap of 2.01 billion GBP. It operates through three divisions: Ashfield, Sharp, and Aquilant. It has a 28.04 P/E ratio. The Ashfield segment offers commercialization and clinical services for the pharmaceutical and healthcare industry that comprise supporting healthcare professionals and patients at various stages of the product life cycle, as well as provides field and contact center sales teams, healthcare communications, patient support, audit, advisory, medical information, and event management services to approximately 300 healthcare companies.